Neurological complications in renal failure: a review

R. Brouns, P. P. De Deyn

Abstract

Neurological complications whether due to the uremic state or its treatment, contribute largely to the morbidity and mortality in patients with renal failure. Despite continuous therapeutic advances, many neurological complications of uremia, like uremic encephalopathy, atherosclerosis, neuropa thy and myopathy fail to fully respond to dialysis. Moreover, dialytic therapy or kidney transplantation may even induce neurological complications. Dialysis can directly or indirectly be associated with dialysis dementia, dysequilibrium syndrome, aggravation of atherosclerosis, cerebrovascular accidents due to ultrafiltration-related arterial hypotension, hypertensive encephalopathy, Wernicke’s encephalopathy, hemorrhagic stroke, subdural hematoma, osmotic myelinolysis, opportunistic infections, intracranial hypertension and mononeuropathy. Renal transplantation itself can give rise to acute femoral neuropathy, rejection encephalopathy and neuropathy in graft versus host disease. The use of immunosuppressive drugs after renal transplantation can cause encephalopathy, movement disorders, opportunistic infections, neoplasms, myopathy and progression of atherosclerosis. We address the clinical, pathophysiological and therapeutical aspects of both central and peripheral nervous system complications in uremia.

Keywords: Renal failure; Uremia; Dialysis; Renal transplantation; Encephalopathy; Neuropathy; Myopathy

Contents
1. Introduction ........................................................................................................ 2
2. Central nervous system complications ........................................................................ 2
  2.1. Encephalopathy .............................................................................................. 2
  2.2. Dementia .................................................................................................... 6
  2.3. Cerebrovascular disease ....................................................................................... 6
  2.4. Osmotic myelinolysis ......................................................................................... 7
  2.5. Movement disorders and restless legs syndrome ................................................................. 8
  2.6. Opportunistic infections ....................................................................................... 8
  2.7. Neoplasms .................................................................................................. 9
  2.8. Intracranial hypertension ...................................................................................... 9
  2.9. Intracranial hypertension ...................................................................................... 9
3. Peripheral nervous system complications ........................................................................ 9
  3.1. Mononeuropathy ............................................................................................. 9
  3.2. Polyneuropathy ............................................................................................ 10
  3.3. Myopathy .................................................................................................. 11
4. Conclusion ........................................................................................................ 11
References ............................................................................................................ 11
1. Introduction

Patients with renal failure often have signs and symptoms related to fluid and electrolyte disturbances, anemia, malnutrition, bone disease and gastrointestinal problems. Vascular and neurologic impairment in particular remain an important source of morbidity and mortality in this vulnerable patient population.

In this paper, disease related and treatment related neurological complications in renal failure will be reviewed. With the introduction of dialysis and renal transplantation, the spectrum of neurological complications changed. The incidence and severity of uremic encephalopathy, atherosclerosis, neuropathy and myopathy have declined but many patients fail to fully respond to dialytic therapy.

Moreover, dialytic therapy or kidney transplantation may even induce neurological complications. Dialysis dementia, dialysis dysaequilibrium syndrome, hypertensive encephalopathy and cerebrovascular accident due to ultrafiltration-related arterial hypotension can occur as a direct consequence of dialysis. Furthermore, dialysis is associated with aggravation of atherosclerosis and can contribute to the development of Wernicke’s encephalopathy, hemorrhagic stroke, subdural hematoma, osmotic myeliniolysis, opportunistic infections, intracranial hypertension and neuropathy. Patients with renal failure may benefit from kidney transplantation, but the use of immunosuppressive drugs can cause encephalopathy, movement disorders, opportunistic infections, neoplasms, myopathy and progression of atherosclerosis. Renal transplantation itself can give rise to acute femoral neuropathy, rejection encephalopathy and neuropathy in graft versus host disease (Table 1). In what follows, we will address both central and peripheral nervous system complications in patients with renal failure.

2. Central nervous system complications

2.1. Encephalopathy

In patients with renal failure, encephalopathy is a common problem that may be caused by uremia, thiamine deficiency, dialysis, transplant rejection, hypertension, fluid and electrolyte disturbances or drug toxicity [1] (Table 2). In general, encephalopathy presents with a symptom complex progressing from mild sensorial clouding to delirium and coma. It is often associated with headache, visual abnormalities, tremor, asterixis, multifocal myoclonus, chorea and seizures. These signs fluctuate from day to day or sometimes from hour to hour [2].

Uremic encephalopathy may accompany acute or chronic renal failure, but in patients with acute renal failure the

<table>
<thead>
<tr>
<th>Neurological complication</th>
<th>Pathophysiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wernicke’s encephalopathy</td>
<td>Accelerated loss of thiamine in hemodialysis</td>
</tr>
<tr>
<td>Dialysis dementia</td>
<td>Aluminium-containing dialysate</td>
</tr>
<tr>
<td></td>
<td>Aluminium-based phosphate binders</td>
</tr>
<tr>
<td>Rejection encephalopathy</td>
<td>Cytokine production in renal transplant rejection</td>
</tr>
<tr>
<td>Dysaequilibrium syndrome</td>
<td>Reverse urea effect in dialysis</td>
</tr>
<tr>
<td></td>
<td>Intracellular acidosis in cerebral cortex</td>
</tr>
<tr>
<td>Immunosuppressiva-associated encephalopathy</td>
<td>Disruption blood-brain barrier, axonal swelling, extracellular edema, demyelination, drug metabolites, microvascular damage</td>
</tr>
<tr>
<td>Ischemic stroke</td>
<td>↑ Atherosclerosis due to unstable dialysate calcium concentration,</td>
</tr>
<tr>
<td></td>
<td>bioincompatibility in dialysate, calcium-containing phosphate binders,</td>
</tr>
<tr>
<td></td>
<td>immunosuppressive</td>
</tr>
<tr>
<td>Multi-infarct dementia</td>
<td>Intradialytic hypertension</td>
</tr>
<tr>
<td>Hypertensive encephalopathy</td>
<td>Cerebral vasogenic edema due to (intradialytic) hypertension</td>
</tr>
<tr>
<td>Intraduodenal hemorrhage</td>
<td>Anticoagulation in hemodialysis</td>
</tr>
<tr>
<td>Subdural hematoma</td>
<td>Anticoagulation in hemodialysis, rapid ultrafiltration, use of hypertonic dialysate</td>
</tr>
<tr>
<td>Osmotic myeliniolysis</td>
<td>Rapid correction of chronic hypo- or hyperosmolar state, eventually by dialysis</td>
</tr>
<tr>
<td>Movement disorders</td>
<td>Drug-induced in hemodialysis patients</td>
</tr>
<tr>
<td></td>
<td>Immunosuppressive agents (cyclosporine, tacrolimus)</td>
</tr>
<tr>
<td>Opportunistic infections</td>
<td>↑ Infection hazard and immunosuppression in dialysis immunosuppressiva in renal transplant patients</td>
</tr>
<tr>
<td>Neoplasms</td>
<td>Immunosuppression due to dialysis immunosuppressiva in transplant patients</td>
</tr>
<tr>
<td>Intracranial hypertension</td>
<td>Pseudolobatum cerebi secondary to dialysis or steroids</td>
</tr>
<tr>
<td>Carpal tunnel syndrome</td>
<td>Compression median nerve by arteriovenous fistula or dialysis-associated</td>
</tr>
<tr>
<td></td>
<td>amyloidosis</td>
</tr>
<tr>
<td>Acute femoral neuropathy</td>
<td>Compression or ischemia during renal transplantation</td>
</tr>
<tr>
<td>Non-uremic neuropathy</td>
<td>Graft vs. host disease in transplant patients</td>
</tr>
<tr>
<td>Steroid-induced myopathy</td>
<td>Use of steroids, especially in transplant patients</td>
</tr>
</tbody>
</table>
Table 2

<table>
<thead>
<tr>
<th>Encephalopathy</th>
<th>(Presumed) pathophysiology</th>
<th>Therapeutic or preventive measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uremic encephalopathy</td>
<td>Accumulation of neurotoxins</td>
<td>Dialysis or kidney transplantation</td>
</tr>
<tr>
<td></td>
<td>Disturbance of intermediary metabolism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hormonal disturbances</td>
<td></td>
</tr>
<tr>
<td>Wernicke’s encephalopathy</td>
<td>Thiamine deficiency</td>
<td>Thiamine administration</td>
</tr>
<tr>
<td>Dialysis encephalopathy/dementia</td>
<td>Aluminium accumulation</td>
<td>Use of aluminium-free dialysate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Avoid aluminium-based phosphate binders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Administration of deferoxamine</td>
</tr>
<tr>
<td>Rejection encephalopathy</td>
<td>Cytokine production due to rejection process</td>
<td>↑ Immunosuppression</td>
</tr>
<tr>
<td>Hypertensive encephalopathy</td>
<td>Cerebral vasogenic edema</td>
<td>Antihypertensive treatment</td>
</tr>
<tr>
<td>Dysequilibrium syndrome</td>
<td>Reverse urea effect</td>
<td>Self-limited</td>
</tr>
<tr>
<td></td>
<td>Intracellular acidosis in cerebral cortex</td>
<td></td>
</tr>
<tr>
<td>Fluid and electrolyte disturbances</td>
<td>↑ Calcium, magnesium, sodium, osmolality</td>
<td>Correction of electrolyte imbalance</td>
</tr>
<tr>
<td></td>
<td>↓ Sodium, osmolality</td>
<td></td>
</tr>
<tr>
<td>Drug toxicity</td>
<td>Drugs metabolised or excreted by kidney</td>
<td>Dose reduction or cessation</td>
</tr>
<tr>
<td></td>
<td>Immunosuppressive drugs</td>
<td></td>
</tr>
</tbody>
</table>

Symptoms are generally more pronounced and progress more rapidly [2,3]. Besides the general symptom complex of encephalopathy, focal motor signs and the “uremic twitch-convulsive” syndrome can be seen [2,4]. Even in patients with neurologically asymptomatic chronic renal disease, impaired cognitive processing can be disclosed by event-related potentials. Increase in P3 latency and decrease in P3 amplitude is found. After hemodialysis, significant improvement occurs, but the level of azotemia correlates poorly with the degree of neurological dysfunction [3]. Electroencephalographic findings in uremic encephalopathy are non-specific but correlate with clinical symptoms and therefore may be of diagnostic value especially if serial studies are performed. Typically, generalised slowing with an excess of delta and theta waves and sometimes bilateral spike-wave complexes are found (Fig. 1). With progression of the uremic state, the electroencephalogram becomes slower [2,3]. Cerebral imaging is not necessary for the diagnosis, but is useful to ex-

![Electroencephalographic findings in a patient with uremic encephalopathy, showing generalised slowing with an excess of delta and theta waves and bilateral spikes.](image-url)
clude other causes of confusion. The pathophysiology of uremic encephalopathy is complex and poorly understood. Accumulation of metabolites, hormonal disturbance, disturbance of the intermediary metabolism and imbalance in excitatory and inhibitory neurotransmitters have been identified as contributing factors. Renal failure results in accumulation of numerous organic substances that possibly act as uremic neurotoxins, but no single metabolite has been identified as the sole cause of uremia. Symptoms are usually alleviated by dialysis or successful renal transplantation. Accumulation of urea, guanidino compounds, uric acid, hippuric acid, various amino acids, polypeptides, polyamines, phenols and conjugates of phenol, phenolic and indolic acids, acetone, glyceric acid, carnitine, myoinositol, sulphates, phosphates and “middle molecules” has been reported in the literature. Among the guanidino compounds, guanidinosuccinic acid, methylguanidine, guanidine and creatinine were found to be highly increased in serum, cerebrospinal fluid and brain of uremic patients. It is postulated that these compounds may contribute to the epileptic and cognitive symptoms accompanying uremic encephalopathy. Activation of the excitatory N-methyl-D-aspartate receptors and concomitant inhibition of inhibitory GABA receptors is an essential mediator of neurotransmitter release and plays a major role in intracellular metabolic and enzymatic processes, alterations in brain calcium may possibly disrupt cerebral function by interfering with any of these processes. Wernicke’s encephalopathy typically presents with the triad of ophthalmoplegia, ataxia and cognitive symptoms or disturbances of consciousness. Because this triad is rarely present and because of similarities with uremic encephalopathy, this disorder often remains unrecognized with high fatality as a consequence. A good outcome however, can be obtained if thiamine is administered immediately. Dialysis encephalopathy in uremic patients is rare, but especially hemodialysis patients are at risk because not only low thiamine intake but probably also accelerated loss of thiamine.

Dialysis encephalopathy or dialysis dementia is a subacute, progressive and often fatal disease that presents with dysarthria, dysphasia, apraxia, personality changes, psychosis, myoclonus, seizures and finally dementia. In most cases, it progresses to death in 6 months. Errors in dialysis water purification or the use of aluminium-containing dialysate and aluminium-based phosphate binders to treat hyperphosphatemia causes accumulation of this element in many organs, inducing microcytic anemia, osteomalacia and dialysis encephalopathy. Chelation with deferoxamine is the treatment of choice. Dialysis encephalopathy is rare nowadays, but sporadic cases due to the use of aluminium hydroxide occur.

Rejection encephalopathy presents with headache, confusion or convulsions in a patient with systemic features of acute graft rejection. Over 80% of cases occurs within 3 months of transplantation, but cases up to 2 years after transplantation have been reported. The overall prognosis is good, with rapid and complete recovery after treatment of the rejection episode. Electroencephalography, neuroimaging and lumbar puncture do not contribute to the diagnosis. Pathophysiologically, cytokine production secondary to the rejection process may be important.

In hypertensive encephalopathy, patients display the encephalopathic symptom complex in combination with severe hypertension. Magnetic resonance imaging often demonstrates posterior leukoencephalopathy (Fig. 2). Accurate diagnosis and immediate antihypertensive treatment is regarded as a medical emergency since symptoms and imaging abnormalities may be reversible. Hypertensive encephalopathy is thought to be caused by vasogenic edema predominantly in the posterior areas of the brain due to impaired cerebrovascular autoregulation, endothelial injury and elevated plasma concentrations of natriuretic peptides. Recombinant human erythropoietin for correction of renal anemia is known to cause hypertension in about 35% of the patients. Hypertensive encephalopathy is estimated to occur in 5% (23–25). This complication is unrelated to the extent or rate of increase in hematocrit, but is associated with a rapid increase in blood pressure even in previously normotensive patients. Monitoring of blood pressure, gradually increasing doses of recombinant erythropoietin and administration of...
conventional antihypertensive therapy, often prevent this complication [26, 27]. However, if hypertension persists, recombinant erythropoietin should be reduced in dose or temporarily discontinued [26].

Dialytic treatment can be associated with the dialysis dysequilibrium syndrome which typically presents clinically with headache, nausea, muscle cramps and twitching, delirium and seizures [28]. The dys-equilibrium syndrome tends to be self-limiting and subsides over several hours to days [3]. In literature, controversy concerning the pathogenesis of this condition exists. The “reverse urea hypothesis” suggests that during hemodialysis, urea is cleared more slowly from brain than from blood causing an osmotic gradient that leads to net flow of water into the brain resulting in transient cerebral edema [29, 30, 31]. Other studies however, demonstrated that urea is cleared from brain and blood at the same rate [32]. The “idiogenic osmole hypothesis” proposes that an osmotic gradient between brain and plasma develops during rapid dialysis because of newly formed brain osmoles, identified as amino acids, polyols and trimethylamines [29, 33]. An alternative hypothesis suggests that the cerebral edema is caused by intracellular acidosis in the cerebral cortex due to increased production of organic acids [3, 4]. Slow dialysis and addition of osmotically active solute to the dialysate can prevent the condition [5].

Fluid and electrolyte disturbances are common in patients with renal failure and can produce central nervous system depression with encephalopathy as the major clinical manifestation. Especially hypercalcemia, hypermagnesemia, hypo- and hypernatremia, hypo- and hyperosmolality are known to cause this problem [34, 35]. Symptoms subside after correction of the electrolyte imbalance.

Encephalopathy due to drug toxicity is often seen in patients with kidney failure and mainly occurs with drugs that are normally metabolised or excreted by the kidney like isoniazide, encaidine, pseudopephedrine, metronidazole, vigabatrin, acyclovir, radiographic contrast and cefazolin [36–43]. Further, it has been demonstrated that protein binding of several drugs (phenytoin, theophylline, diazepam, prazosin, imipramine, propranolol, cimetidine, clonidine and methotrexate) can be altered in chronic renal failure, which not only might affect the therapeutic effectiveness of these drugs, but also could result in neurotoxicity [44]. Immunosuppressant-associated encephalopathy has been described with the calcineurin inhibitors cyclosporine [45] and tacrolimus (FK506) [46] and to a lesser extend with muromonab-CD3 (OKT3) [47]. Neurotoxicity associated with these drugs is more frequent when toxic levels accumulate in the body but may even be apparent at levels within therapeutic range. Common manifestations are tremor, headache, cerebellar or extrapyramidal signs [48–50]. The most serious complication is reversible posterior leukoencephalopathy [46] with subcortical and deep white matter changes [22, 51, 52] resembling upon imaging to those found in hypertensive encephalopathy. Cerebral cortex involvement and contrast enhancement have occasionally been noted [53]. Recognition of immnosuppressant-associated encephalopathy is important, since dose reduction or discontinuation of immunosuppressive drugs mostly results in resolution of clinical symptoms and neuroimaging abnormalities. The etiology of neurotoxicity associated with cyclosporin and tacrolimus is not fully understood and probably multifactorial [53]. Disruption of the blood–brain barrier, which could facilitate the passage of substances into the cerebral interstitium, causing axonal swelling and extracellular edema has been postulated. But also demyelination has been described. This may be the result of inflammatory or ischeinic phenomena, the latter possibly due to loss of local vascular regulation or direct vascular toxicity. Other hypotheses include production of active drug metabolites or microvascular damage due to endothe-

Fig. 2. Initial MRI study in a patient with severe hypertension, headache, confusion and visual disturbances reveals typical subcortical edema in the occipital regions with only minimal cortical involvement (arrows) on axial FLAIR sequence (A). One week later, after antihypertensive treatment and clinical improvement, follow-up MRI study reveals complete resolution of the lesions on FLAIR images (B).
Dementia is more common in patients with renal failure than in the general population. The incidence of dementia in aged patients undergoing dialysis is estimated at 4.2% [56], with predominant occurrence of multi-infarct dementia [57,58]. The incidence of multi-infarct dementia in this group is estimated at 3.7% [56], which is 7-8 times more frequent than in the general elderly population. This can be explained by the unfavourable cerebrovascular risk profile in these patients.

Dementia should be differentiated from delirium and depression, which are also common problems in renal failure. Subacute and fast progressive dementia can occur in progressive multifocal leukoencephalopathy and dialysis dementia.

Cerebral atrophy is common in patients with chronic renal failure, even in patients without evident cognitive, affective or behavioural changes [59-61]. However, on psychometric testing, there is often evidence of intellectual deficits. The atrophy might be caused by endogenous uremic toxins, arterial hypertension or cerebral hyperperfusion due to atherosclerosis [62-64].

2.3. Cerebrovascular disease

Cerebrovascular disease is a predominant cause of morbidity and mortality in patients with chronic renal failure. This population is prone to the development of atherosclerosis, thromboembolic disease or intradialytic hypotension. But the presence of several risk factors also predisposes to hemorrhagic complications.

Ischemic stroke in renal failure mainly results from atherosclerosis, thromboembolic disease or intradialytic hypotension.

Atherosclerosis in patients with chronic renal failure is generally more diffuse and distally located than in the general population, probably because of combination of traditional atherogenic risk factors such as male gender, age, diabetes mellitus, hypertension, dyslipidemia and smoking with factors more specifically related to renal failure and its treatment [65-67]. In particular, renal failure is or may be associated with accumulation of guanidino compounds, oxidative and carbonyl stress, hyperhomocysteinemia and disturbances of the calcium-phosphate metabolism [68-72].

Accumulation of endogenous guanidino compounds in chronic renal failure may play an important role in endothelial dysfunction. Especially, the l-arginine analogues N\textsubscript{0}-N\textsubscript{0}'-asymmetrical dimethylarginine (ADMA) and N\textsubscript{0}'-monomethyl-l-arginine (l-NMMA) can competitively inhibit the synthesis of nitric oxide, that mediates the vasodilator effects of endothelium-derived relaxing factor and consequently plays a role in determining vasmotor tone in several vascular beds, including the cerebral circulation [68,70,73]. Furthermore, recent research suggests that the guanidino compound guanidino-succinic acid might potentiate the deleterious effects of cerebral hypoxia under uremic conditions [74]. Therefore, guanidino compounds should be considered as possible uremic toxins that may play a significant role in the cerebrovascular and neurological disorders observed in uremia [70].

Elevated plasma S-nitrosothiol levels in hemodialysis patients have been reported and a protective role against nitrosative stress in uremia is suggested [75]. However, a lack of S-nitrosothiol bioavailability has been described, which could contribute to the high cardiovascular risk of patients with chronic renal failure [76].

Oxidative and carbonyl stress in chronic renal failure are associated with the inflammatory state that plays a role in arterogenesis [77]. Besides oxidation of low-density lipoproteins [78,79], elevated levels of advanced glycation end products (AGEs) have been described in patients with renal failure. This phenomenon has been attributed to impaired renal clearance of AGEs, in combination with increased endogenous formation and dietary intake [80]. Therapeutic strategies to reduce AGEs may involve dialysis technique and inhibition of AGE formation. Daily hemodialysis, online hemodiafiltration, the use of ultrapure dialysate and peritoneal dialysate free of reactive carbonyl compounds are useful measures [81,82]. Inhibition of AGE formation can be achieved by angiotensin converting enzyme inhibitors, angiotensin receptor blockers or aminoguanidine [81].

Large observational studies established that hyperhomocysteinemia is an independent risk factor for atherosclerosis [83]. The prevalence of hyperhomocysteinemia in patients with chronic renal failure is estimated to be 85-100%, but the cause is obscure [71,84,85]. Therapeutic intervention with high dosage folic acid and oral Vitamin B or L-5-methyltetrahydrofolate can reduce homocysteine levels in this patient population [86,87] but without evidence of improvement of endothelial function [88,89]. Unfortunately, most hemodialysis and renal transplant patients are partially refractory to this treatment regimen [90]. Enhanced dialysis over super-flux membranes is a more efficient strategy to reduce homocysteine levels. This is probably the result of improved removal of uremic toxins with inhibitory activities against homocysteine-metabolizing enzymes, rather than better dialytic clearance of homocysteine itself [91-94]. Homocysteine levels also decrease after renal transplant, but tend to remain higher than normal [71].

Soft tissue calcification, with an increased risk of vascular calcification, arterial stiffness and worsening of atherosclerosis can also occur due to disturbances of the calcium metabolism [95]. Secondary hyperparathyroidism due to
reduced active Vitamin D production by the kidneys and phosphate retention, can lead to tertiary hyperparathyroidism. Vitamin D supplementation is important in prevention and management of secondary hyperparathyroidism. Hyperphosphatemia is usually treated by means of intestinal phosphate binders. Calcium-containing phosphate binders can aggrava
tion be useful, especially in patients with metastatic calcification and/or hypercalcemic episodes. Surgical parapharyngeal discomanagement of treating hypercalcemic hyperparathyroidism, when medical therapy has failed.

Treatment of renal failure can have a detrimental effect on atherosclerosis. Dialysis by itself appears to promote the development of arterial disease, maybe due to bio- incompatibility or oxidative stress [76]. Furthermore, progression of atherosclerosis may be influenced by the use of immunosuppressive agents used in renal transplant recipients [65]. Many studies suggest that immune mechanisms are involved in the development of atherosclerotic plaques, which harbour a significant proportion of activated T lymphocytes [96].

Thromboembolic ischemic CVA may result from either characteristic cardiac disease in chronic renal failure, e.g., dilated cardiomyopathy and arrhythmias [97,98] or “artery-
to-artery embolism” due to severe atherosclerosis. Ultrafiltration-related arterial hypotension is a common complication of hemodialysis, especially in older patients with anemia [99]. Autonomic neuropathy also plays an important role [100]. Severe arterial hypotension can result in cerebral hypoperfusion and eventually ischemic stroke which is typically located in the boundary zones between the vascular territories of the anterior and middle cerebral artery or between the middle and the posterior cerebral artery [101]. Treatment consists of infusion with saline [102]. The use of sodium profiling, cool dialysate, midodrine and possibly sertraline can increase hemodynamic stability during dialysis [103,104].

Since renal anemia is an indepent risk factor for stroke and cardiovascular events in chronic renal failure [105,106], treatment with recombinant human erythropoietin seems an important preventive measure.

Hemorrhagic stroke may include intracerebral, subarachnoid or subdural hemorrhage. The uremic state causes platelet dysfunction and altered platelet-vessel wall interaction resulting in a bleeding tendency [107]. This is partially corrected by effective dialysis, but hemodialysis by itself is associated with a higher incidence of intracerebral hemorhage (8.7 to 10.3 per 1000 patient years, relative risk compared to normals 10.7) and subarachnoidal hemorrhage (0.8 per 1000 patient years, relative risk compared to normals 4.0) [66,108,109]. Furthermore, prognosis of hemorrhagic stroke in patients with chronic renal failure is poor with high morbidity and mortality up to 60% [66,110–112].

The predestination of patients renal failure for intracerebral and subarachnoidal hemorrhage is multifactorial. Hypertension, polycystic kidney disease and the use of anticoagulation or platelet antaggregants are the most important risk factors [109,111,113,114]. The mutations in the PKD-1 or -2 gene in patients with autosomal dominant polycystic kidney disease account for an 10-fold increased risk for development of cerebral vascular malformations, i.e., saccular aneurysms and dolichoectasia. There is a tendency for these malformations to cluster in families and to rupture more frequently and earlier, mostly resulting in subarachnoidal hemorrhage [3,115–118]. The use of heparin during hemodialysis and coumarin or platelet antaggregants in the prevention of fistula thrombosis probably further elevates the risk of hemorrhagic stroke [111,112,114]. Hemodialytic strategies to reduce bleeding risk include the use of regional or minimal heparinisation. Dialytic modalities that completely preclude systemic anticoagulation, i.e. peritoneal dialysis or heparin-free dialysis are mostly indicated for patients who are actively bleeding or recently suffered from a cerebral hemorrhage [111,119].

Systemic anticoagulation in hemodialysis can also be complicated by acute and chronic subdural hematoma. Other predisposing factors are hypertension, head trauma, rapid ultrafiltration and the use of hypertonic dialysate [120]. The occurrence of subdural hematoma is well known but frequently overlooked because of clinical similarity with encephalopathy and dementia. However, diagnosis can easily be made by cerebral imaging. Neurosurgical intervention, if necessary, can be done by burr hole aspiration or craniotomy. However, conservative therapy with replacement of hemodialysis by peritoneal dialysis or continuation of hemodialysis without anticoagulation is often sufficient [121–123].

2.4. Osmotic myelinolysis

Osmotic myelinolysis in patients with renal failure mainly occurs within the central basis pontis, but extrapontine regions including the midbrain, thalamus, basal nuclei and cerebellum can be affected as well. Central pontine myelinolysis is clinically characterized by acute progressive quadriplegia, dysarthria, dysphagia and alterations of consciousness. With expansion of the demyelination through the midbrain, horizontal and vertical gaze paralysis can be seen. Parkinsonism or ataxia can occur when respectively the basal nuclei or the cerebellum are affected.

On magnetic resonance imaging (MRI), T2-weighted images demonstrate hyperintense patchy areas of demyelination [124]. The prognosis is often fatal and in those who survive, maximum recovery may require several months. Treatment is supportive only. In view of the hypothetical pathogenesis, it probably is important to correct chronic hyponatremia slowly and to avoid hyponatremia.
The exact pathogenetic mechanisms leading to osmotic myelinolysis are still unclear. It is postulated that glial cell edema, which is caused by fluctuating osmotic forces, results in compression of fiber tracts and induces demyelination and eventually cell death. Cellular edema can be precipitated by aggressive correction of a chronic hypopotassemia or hyperosmolar state [125]. Osmotic myelinolysis after rapid correction of prolonged hyponatremia—or less frequent hypernatremia—by dialysis is a known problem [126]. On the other hand, rapid serum sodium correction by hemodialysis occurs often, but only few patients develop demyelination.

2.5. Movement disorders and restless legs syndrome

Movement disorders in patients with renal failure can occur as a result of encephalopathy, medication or structural lesions.

Several types of involuntary movements can occur in metabolic encephalopathy. Asterixis or “flapping tremor” is probably caused by sudden loss of tonus, originating from cortical dysfunction and clinically consists of multifocal action-induced jerks that can even mimic drop attacks in severe cases [127,128]. In myoclonus, the patient exhibits shock-like contractions of a muscle or a group of muscles. These contractions are irregular in rhythm and amplitude and are followed by relaxation. In uremia, both spontaneous action myoclonus and stimulus–sensitive myoclonus with good response to benzodiazepines can occur [129]. It has been suggested that uremic myoclonus is caused by a disturbance of function in the lower brainstem reticular formation due to water-electrolyte imbalance leading to microcirculatory and degenerative changes [130]. A typical movement disorder in uremic encephalopathy is the uremic “twitch-convulsive” syndrome that consists of intense asterixis and myoclonic jerks that are accompanied by fasciculations, muscle twitches and seizures [2,4]. Finally, thiamine deficiency is thought to cause a dysfunction of the basal ganglia which may induce chorea [131].

Drug-induced involuntary movements in patients with chronic renal failure are more frequently seen in patients after kidney transplantation. Neurotoxic effects of immunosuppressive agents like cyclosporine and tacrolimus may manifest as tremor or other extrapyramidal signs [50].

Secondary to cerebrovascular disease, extrapontine myelinolysis, intracerebral neoplasms and opportunistic infections, patients with chronic renal failure are prone to development of structural lesions, which can be located in the basal ganglia and thus induce extrapyramidal movement disorders. Furthermore, acute movement disorders can be caused by bilateral basal ganglia lesions due to hypoperfusion with global brain ischemia and selective vulnerability of the basal ganglia to hypoxemia and uremic toxins [132].

The restless legs syndrome is a common and incapacitating disorder that is characterized by an imperative need to move the legs because of paresthesias that worsen during periods of inactivity. As a consequence, patients suffer from severe sleep disturbances. At least 20% of patients with chronic renal failure suffer from this incapacitating disorder [133,134]. In general, dialysis does not substantially improve uraemic restless legs syndrome, but cool dialysate fluid (36.5 °C) has been linked to some relieve [135]. Treatment with levodopa, dopamine agonists, benzodiazepines, gabapentin, clonidine or opioids may bring relief [136–139]. Substantial improvement of restless legs symptoms after kidney transplantation has been described [140]. The etiology is uncertain, but the association with peripheral neuropathy and chronic renal failure is well known.

2.6. Opportunistic infections

Since the usual signs of infection in immunosuppressed patients are blunted and since infection with uncommon and atypical opportunistic organisms often occurs, early diagnosis may be difficult. Treatment with antimicrobial therapy and decrease of immunosuppressive agents should not be delayed. Neurological infections in patients with renal failure mainly present as acute, subacute or chronic meningitis, encephalitis, myelitis or brain abscess [141,142]. Opportunistic bacterial infections include pathogens as Nocardia asteroides, Mycobacterium tuberculosis and Listeria monocytogenes [143]. Fungi are often represented by Cryptococcus neoformans, Aspergillus fumigatus, Candida, Pneumocystis carinii, Histoplasma, Mucor and Paecilomyces species [144]. Reactivation of latent viral infection with herpes simplex, cytomegalovirus and JC Polyomavirus are not uncommon [145,146]. Infection with cytomegalovirus is the most frequent opportunistic infection following renal transplantation. It is usually asymptomatic, but invasive forms with meningitis, encephalitis, myelitis and involvement of nerve roots can develop. Reactivation of the JC Polyomavirus and infection of oligodendrocytes results in progressive multifocal leukoencephalopathy [146]. Clinical manifestations include severe and rapid progressive dementia, ataxia, visual disturbances and other focal neurologic deficits, generally progressing to a vegetative state within 6 months. Unfortunately, all therapeutic regimens are still in experimental phase. Metronidazol and protozoan infections with Strongyloides stercoralis and Trichomonas vaginalis, respectively, have been described [147].

Lumbar puncture is often needed for diagnosis, but should only be performed after exclusion of intracranial space occupying lesions by neuroimaging. If a definitive diagnosis cannot be made in reasonable time, empirical therapy must be started [3].

Naturally, immunosuppression is the main cause of opportunistic infections. The uremic state itself is associated with a defective phagocytic function of polymorphonuclear white blood cells, leading to an immunodeficiency especially against bacterial infection [148]. This problem is even more prominent in patients with dialysis or renal transplants. Dialysis patients also have an increased hazard of infection, especially fistula and shunt infections [149] and transplant pa-
patients suffer from a severe suppression of cell-mediated immunity, due to use of immunosuppressant agents.

2.7. Neoplasms

The immunosuppressive state of patients with renal failure not only predisposes to infection with opportunistic pathogens, but is also associated with an increased incidence of de novo neoplasia [145,150]. Although development of neoplasms in the neurologic system is rare, malignant meningioma [151] and primary central nervous system lymphoma have been described in end stage renal failure [152–155]. Immunosuppressive therapy after renal transplantation is associated with an increased risk of lymphoproliferative disease. The majority of post-transplantation lymphoproliferative disorders (PTLD) are of B-cell origin and contain Epstein–Barr virus [156]. This condition is estimated to occur in 1–2% of renal transplantation patients and generally has a poor clinical outcome [157,158]. With alteration in immunosuppression regimen, the localization of PTLD have changed over time. Central nervous system involvement was the predominant site of disease prior to the use of cyclosporine [159]. With the institution of cyclosporine, thoracic, and abdominal presentations became more common. Standard therapy for PTLD is not well established. Often, immunosuppression is reduced or even ceased, which is associated with an increased risk of allograft rejection [160]. Radiotherapy is often applied for locations in the central nervous system [161]. Aclclovir, surgical excision, several combinations of chemotherapeutic agents and monoclonal antilymphoma immunotherapy have been reported to be useful, often in combined therapy [157,160].

With the increased incidence of ureteral, gastrointestinal, hematologic and endocrine neoplasia in end stage renal disease [150,162], one can expect a higher risk of brain metastasis.

2.8. Intracranial hypertension

Orthostatic headache, occasionally associated with neck stiffness, nausea, visual disturbances, dizziness, hearing loss or abducens nerve palsy strongly suggests intracranial hypertension due to reduction of cerebrospinal fluid pressure [163–165]. Accurate diagnosis is important since subdural hematoma may develop [163,166] and conservative management with bed rest, increased fluid intake and administration of steroids is quite effective [165]. MRI of the head typically shows diffuse pachymeningeal gadolinium enhancement, often with imaging evidence of descent of the brain [167,168]. On radioisotope cisternography, absence of activity over the cerebral convexities, even at 24 or 48 h is seen and sometimes the level of the leak can be revealed [164]. Diagnosis can be confirmed by measuring cerebrospinal fluid pressure [165]. This condition may occur spontaneously [163], secondary to cerebrospinal fluid leakage or more rarely in dehydrated and uremic.[9. Intracranial hypertension

Intracranial hypertension in patients with chronic renal failure can be idiopathic or secondary to dialysis, use of steroids, or intracranial lesion (neoplasm, infection, cerebrovascular disease) [169]. The diagnostic criteria of idiopathic intracranial hypertension or pseudotumor cerebri include symptoms due to elevated intracranial pressure, normal findings on neuroimaging studies, excluding non-specific findings of raised intracranial pressure and increased cerebrospinal fluid pressure with a normal composition [170]. Clinically, intracranial hypertension manifests with headache, transient visual obscurations, and diplopia due to unilateral or bilateral sixth nerve palsy. Non-specific symptoms may include dizziness, nausea, vomiting, and tinnitus. The increase in intracranial pressure is transmitted to the structures within the intracranial cavity, including the optic nerves resulting in papilledema and progressive optic atrophy with accompanying constriction of the visual field, loss of colour vision and eventually blindness. The treatment goal is to prevent visual impairment by managing the increased intracranial pressure by management of the underlying renal disease and if possible use of acetazolamide, furosemide or corticosteroids [169,171]. Optic nerve sheath fenestration or lumbarperitoneal, ventriculoperitoneal or ventriculocistern shunting procedure should be considered in patients with deterioration of visual function despite maximum medical treatment [169].

3. Peripheral nervous system complications

3.1. Mononeuropathy

In uremia, susceptibility of the peripheral nerves to compression and local ischemia is increased. In practice especially the ulnar, median and femoral nerves are affected (Table 3). Damage to the ulnar nerve can occur by uremic tumoral calcinosis at the wrist, in Guyon’s canal [172]. Depending on the site of compression in the canal, this may cause purely motor dysfunction with paresis of intrinsic hand muscles, sensory loss to the hypothenar eminence, the small finger and the lateral part of the ring finger or mixed symptomatology. Electromyography and nerve conduction studies are useful to confirm the area of entrapment and to document the extent of the pathology. If conservative treatment with anti-inflammatory medication, tricyclic antidepressants, anticonvulsants and splinting show no response or if motor deficits develop, surgical neurolysis is indicated.

The carpal tunnel syndrome is far more common and is caused by entrapment of the median nerve in the carpal tunnel, which is formed by the flexor retinaculum and the carpal bones. Symptoms include burning pain and paresthesias involving the ventral surface of the hand and fingers I–III and medial surface of finger IV. Thenar muscle atrophy may oc-
Mononeuropathy

Ulnar nerve
- Ischemia
  - Anti-inflammatory drugs
- Entrapment in Guyon’s canal due to uremic tumoral calcinosis
  - Tricyclic antidepressants
- Entrapment in carpal tunnel due to dialysis-associated amyloidosis, uremic tumoral calcinosis, arteriovenous fistula
  - Anticoagulants
  - Surgical decompression
  - Optimal dialysis technique
  - Local injection of corticosteroids
  - Surgical decompression
  - Renal transplantation

Median nerve
- Ischemia
  - Local injection of corticosteroids
  - Surgical decompression
  - Renal transplantation

Femoral nerve
- Ischemia
  - Mostly spontaneous recovery
- Entrapment in the carpal tunnel due to uremic tumoral calcinosis or due to nerve ischemia

Polyneuropathy

Uremic
- Dialyzable neurotoxins
  - Vitamin supplements (biotin, pyridoxine, cobalamin, thiamine)
  - Tricyclic antidepressants
  - Anticoagulants
  - Dialysis
  - Renal transplantation

Non-uremic
- Graft vs. host disease
  - Specific treatment for underlying disease

Table 3

Neuropathy in renal failure

<table>
<thead>
<tr>
<th>Neuropathy</th>
<th>Pathophysiology</th>
<th>Therapeutic or preventive measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mononeuropathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ulnar nerve</td>
<td>Ischemia</td>
<td>Anti-inflammatory drugs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median nerve</td>
<td>Ischemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Femoral nerve</td>
<td>Ischemia</td>
<td>Mostly spontaneous recovery</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyneuropathy</td>
<td>Uremic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dialyzable neurotoxins</td>
<td>Vitamin supplements (biotin, pyridoxine, cobalamin, thiamine)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tricyclic antidepressants</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anticoagulants</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dialysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal transplantation</td>
</tr>
</tbody>
</table>

3.2. Polyneuropathy

Uremic polyneuropathy occurs in approximately 60% of patients with chronic renal failure and can affect motor, sensory, autonomic and cranial nerves. It has an unexplained male predominance and clinically presents with symmetrical distal sensory loss for all modalities, which is more pronounced in the lower extremities. Mostly, the adverse effects on the peripheral nervous system are minimal as long as the glomerular filtration rate exceeds roughly 12 mL/min. At glomerular filtration rates below this value, nerve conduction studies become abnormal and patients begin to demonstrate clinical signs of peripheral nerve dysfunction when about 6 mL/min is reached. An early finding is elevation of the vibratory threshold and impaired temperature sensibility. Paradoxical heat sensation, paresthesias or pain are common. Later in the course, ascending hypohyesis to pinprick or touch, areflexia, restless legs, muscle weakness, cramps and atrophy can be found. The neuropathy usually evolves over several months but rarely an acute or subacute course is seen. Pruritus is often present in renal failure, especially during dialysis. Its pathogenesis is not completely understood. Autonomic neuropathy can play a role in the pathogenesis of intradialytic and orthostatic hypotension, incontinence, diarrhea, constipation, esophageal dysmotility, hyperhydrosis and impotence. Cardiovascular autonomic testing should include Tilt-table test and measurement of the beat-to-beat variation in heart rate in the supine position, during deep breathing and Valsalva. Electrophysiologically, mainly axonal loss and secondary demyelination can be found. The most sensitive parameters in the diagnosis of uremic neuropathy are F-wave parameters from the lower limbs, vibration detection thresholds on the foot, the sural nerve sensory action potential and decreased nerve conduction velocity. The vibratory threshold on the foot correlates with the clinical grading of neuropathy. The nerves from the upper extremities on the side of the fistula should not be used in the diagnosis due to numerous mild local nerve lesions. In most patients, uremic neuropathy will stabilize or even improve during chronic dialysis. Paresthesia may improve rapidly once hemodialysis is started, but other symptoms mostly persist. Progression of symptoms despite regular dialysis has been found especially after 10 years and in the elderly, but might be less pronounced when dialysis is performed with biocompatible membranes. Renal transplantation can result in recovery from uremic neuropathy.
neuropathy through remyelination [205,206]. If extended axonal degeneration has developed and large numbers of axons are lost, results of renal transplantation are disappointing [184,185,207]. Improvement after supplementation with biotin, pyridoxine, cobalamin and thiamine has been described, possibly due to stimulation of nerve metabolism and encouragement of regeneration [208,209]. Subcutaneous erythropoetin therapy has been reported to improve motor polyneuropathy in uremic patients, especially non-diabetic individuals. The improvement may reflect remyelination, possibly through direct action of erythropoietin on the peripheral neuronal cells [210]. Symptomatic therapy with tricyclic antidepressants and anticonvulsants can be employed. The factors involved in the development of uremic polyneuropathy remain partly unknown. Since increase of nerve conduction velocities after single dialysis has been described, detoxification, e.g. removal of dialyzable neurotoxins may be important (Table 3) [4,211]. It is important to consider the possibility of non-uremic neuropathy in chronic renal failure patients, like neuropathy with graft versus host disease [212], systemic vasculitides and diabetic polyneuropathy (Table 3) [214].

3.3. Myopathy

Although uremic myopathy is a common finding in patients with end-stage renal disease, some confusion exists about the definition. Usually, this term is used to refer to the constellation of functional and occasionally structural muscle abnormalities in patients with chronic renal failure as a consequence of the uremic state itself [213]. Uremic myopathy usually appears in patients with a glomerular filtration rate under 25 mL/min and the progression parallels the decline of renal function [213]. The overall prevalence is estimated at 50% in dialysis patients. It manifests as proximal limb weakness, with muscle wasting, limited endurance, exercise limitation and rapid fatigability [214]. In general, physical examination, electromyography and muscle enzymes are normal [213]. Muscle biopsy occasionally reveals structural alterations, mainly fiber atrophy that predominantly involves type-II fibers [215,216]. Development of cardiomyopathy can be associated with uremic myopathy. Since no specific treatment exists for uremic myopathy, prevention with high-quality dialysis therapy is important, probably best with high-flux membranes. Furthermore, aerobic exercise training, prevention and treatment of secondary hyperparathyroidism, dietary corrections and treatment of renal anemia with recombinant erythropoietin on the peripheral neuronal cells [210]. Symptomatic therapy with tricyclic antidepressants and anticonvulsants can be employed. The factors involved in the development of uremic polyneuropathy remain partly unknown. Since increase of nerve conduction velocities after single dialysis has been described, detoxification, e.g. removal of dialyzable neurotoxins may be important (Table 3) [4,211]. It is important to consider the possibility of non-uremic neuropathy in chronic renal failure patients, like neuropathy with graft versus host disease [212], systemic vasculitides and diabetic polyneuropathy (Table 3) [214].

4. Conclusion

Neurological complications whether due to the uremic state or its treatment, contribute largely to the morbidity and mortality in patients with renal failure. Despite continuous therapeutic progress, most neurological complications of uremia fail to fully respond to dialysis and many are elicited or aggravated by dialysis or renal transplantation. In order to assure optimal care for patients with renal failure, both neurologists and nephrologists should be familiar with the neurologic complications that almost invariably will occur in these patients. Interdisciplinary collaboration plays an important role in prevention and/or early diagnosis and adequate treatment.

References


neurovascular levels by super-flux dialyzers in hemodialysis patients.


